189 related articles for article (PubMed ID: 24147107)
1. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.
Rajamoorthi A; Shrivastava S; Steele R; Nerurkar P; Gonzalez JG; Crawford S; Varvares M; Ray RB
PLoS One; 2013; 8(10):e78006. PubMed ID: 24147107
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
4. Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.
Bhattacharya S; Muhammad N; Steele R; Kornbluth J; Ray RB
Cancer Prev Res (Phila); 2017 Jun; 10(6):337-344. PubMed ID: 28465362
[TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
7. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
8. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
9. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Li HM; Yang JG; Liu ZJ; Wang WM; Yu ZL; Ren JG; Chen G; Zhang W; Jia J
J Exp Clin Cancer Res; 2017 Jan; 36(1):7. PubMed ID: 28061878
[TBL] [Abstract][Full Text] [Related]
10. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
11. Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Xu Y; Zhou J; Carey TE; McHugh JB; Voorhees JJ; Fisher GJ
Neoplasia; 2012 Nov; 14(11):1015-22. PubMed ID: 23226095
[TBL] [Abstract][Full Text] [Related]
12. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
[TBL] [Abstract][Full Text] [Related]
13. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
14. Bioactive phytochemical proanthocyanidins inhibit growth of head and neck squamous cell carcinoma cells by targeting multiple signaling molecules.
Prasad R; Katiyar SK
PLoS One; 2012; 7(9):e46404. PubMed ID: 23050025
[TBL] [Abstract][Full Text] [Related]
15. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
16. Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas.
Sun S; Liu S; Duan SZ; Zhang L; Zhou H; Hu Y; Zhou X; Shi C; Zhou R; Zhang Z
Cancer Res; 2014 Dec; 74(24):7546-59. PubMed ID: 25320014
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
18. Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling.
Sur S; Steele R; Aurora R; Varvares M; Schwetye KE; Ray RB
Cancer Prev Res (Phila); 2018 Apr; 11(4):191-202. PubMed ID: 29061560
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma.
Goto RN; Sobral LM; Sousa LO; Garcia CB; Lopes NP; Marín-Prida J; Ochoa-Rodríguez E; Verdecia-Reyes Y; Pardo-Andreu GL; Curti C; Leopoldino AM
Eur J Pharmacol; 2018 Jan; 819():198-206. PubMed ID: 29221949
[TBL] [Abstract][Full Text] [Related]
20. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
